A Phase 3 interventional study of Insulin glargine/lixisenatide (HOE901/AVE0010) and Insulin glargine (HOE901) in Type 2 Diabetes, sponsored by Sanofi. Completed at 236 sites in 18 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-05-09.
Sponsored by Sanofi · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2 — 4 open to participants now, 6 under way, 1 of them phase 3. Insulin Glargine · Diabetes Mellitus, Type 2.
Among the 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2, this one is the 22nd largest by enrollment of the 175 interventional ones that give a count, is one of 8 that started in 2014, is one of 60 in phase 3, and was the 111th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →4 of the 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:
Sanofi · Sites in China
Ages 18+
Loyola University · Sites in United States
Ages 18+ · Women only
Third Affiliated Hospital, Sun Yat-Sen University · Sites in China
Ages 30–65
Yanbing Li
Ages 18–70
By country, each count listing its studies:
Insulin Glargine: first FDA approval 2000 (LANTUS SOLOSTAR), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
176 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 8 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 736 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 253 across the 175 interventional studies. Of the 161 that completed or were terminated, 56 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
122 of 176 have an industry lead sponsor. The 10 most frequent:
Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
186 studies in Diabetes Mellitus, Type 2 by Sanofi: 1 open now, 1 under way, none of them phase 3. Of 183 finished, 46 (25%) have results posted.
Among the 186 studies in Diabetes Mellitus, Type 2 by Sanofi, this one is the 26th largest by enrollment of the 178 interventional ones that give a count, is one of 6 that started in 2014, is one of 80 in phase 3, and was the 120th registered.
Sanofi’s Diabetes Mellitus, Type 2 studies by the year they started, since 2000.
1 of the studies testing Insulin Glargine in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07173712Yanbing LiRegimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes | 2027-06-30 |
Add it to your calendar (.ics) → With an account.
Among the 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Sanofi’s 186 in Diabetes Mellitus, Type 2:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Primary Objective:
To demonstrate the superiority of the insulin glargine/lixisenatide fixed ratio combination (FRC) to insulin glargine in glycated hemoglobin (HbA1c) change from baseline to Week 30.
Secondary Objective:
To compare the overall efficacy and safety of insulin glargine/lixisenatide FRC to insulin glargine (with or without metformin) over a 30 week treatment period in participants with type 2 diabetes.
Maximum duration of approximately 39 weeks: an up to 8-week screening period, a 30-week randomized treatment period and 3 days post-treatment safety follow up period.
Inclusion criteria :
For participants receiving basal insulin and 1 or 2 oral anti-diabetic drugs (OADs): the OAD dose(s) must be stable during the 3 months before the screening visit. The OADs could be 1 to 2 out of:
Exclusion criteria:
Exclusion criteria for randomization:
The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FRC once daily (QD) for 30 weeks. Dose individually adjusted.
Drug: Insulin glargine/lixisenatide (HOE901/AVE0010) · Drug: Metformin (Background Drug)
Insulin glargine 100 U/mL QD for 30 weeks. Dose individually adjusted.
Drug: Insulin glargine (HOE901) · Drug: Metformin (Background Drug)
Drug pages: Insulin Glargine · Lixisenatide
Insulin glargine/lixisenatide FRC was self-administered by subcutaneous (SC) injection within 1 hour before breakfast using one of 2 SoloStar® pen-injectors: Pen A (ratio of 2 Units (U) of insulin glargine U 100:1 mcg of lixisenatide) or Pen B (ratio of 3 U of insulin glargine U 100:1 mcg of lixisenatide). After run-in, the FRC was initiated at a dose of either 20 U/10 mcg with Pen A or 30 U/10 mcg with Pen B, depending on participant's dose of Insulin glargine on the day prior to randomization. Dose was adjusted weekly to reach and maintain fasting self-monitored plasma glucose (SMPG) of 80 mg/dL to 100 mg/dL (4.4 mmol/L to 5.6 mmol/L). Pen A was used for administration of doses up to 40 U/20 mcg and Pen B for administration of doses from 30 U/10 mcg up to 60 U/20 mcg.
Insulin glargine was self-administered QD by SC injection at approximately the same time every day. After screening, eligible participants entered 6 week run-in phase during which they were switched (if necessary) to insulin glargine and dose was stabilized. The first dose after randomization was same as the one administered on the day prior to randomization and then dose was adjusted weekly to reach and maintain fasting SMPG of 80 mg/dL to 100 mg/dL (4.4 mmol/L to 5.6 mmol/L).
Also known as: Lantus
Pharmaceutical form: Tablet; Route of administration: Oral administration
Change in Glycated Hemoglobin (HbA1c) From Baseline to Week 30
Change in HbA1c was calculated by subtracting baseline value from Week 30 value.
Time frame: Baseline, Week 30
Percentage of Participants With HbA1c <7.0% or ≤6.5% at Week 30
Time frame: Week 30
Change in 2-hour Plasma Blood Glucose Excursion From Baseline to Week 30
Plasma glucose excursion = 2-hour postprandial glucose (PPG) minus plasma glucose value obtained 30 minutes prior to the start of the meal and before investigational medicinal product (IMP) administration, if IMP was injected before breakfast. Change in plasma glucose excursions was calculated by subtracting baseline value from Week 30 value.
Time frame: Baseline, Week 30
Change in Body Weight From Baseline to Week 30
Change in body weight was calculated by subtracting baseline value from Week 30 value.
Time frame: Baseline, Week 30
Mean Change in 7-point Self-monitored Plasma Glucose (SMPG) Profile From Baseline to Week 30
Participants recorded a 7-point plasma glucose profile measured before and 2-hours after each meal and at bedtime, two times in a week before baseline, before visit Week 12 and before visit Week 30 and the average value across the profiles performed in the week before a visit for the 7 time points was calculated. Change in average 7 point SMPG was calculated by subtracting baseline value from Week 30 value. The analysis included all scheduled measurements obtained during the study. The missing data was handled by mixed effect model with repeated measures (MMRM) approach.
Time frame: Baseline, Week 30
Percentage of Participants Reaching HbA1c <7.0% With No Body Weight Gain at Week 30
Time frame: Week 30
Change in Daily Insulin Glargine Dose From Baseline to Week 30
Time frame: Baseline, Week 30
Percentage of Participants Reaching HbA1c <7.0% With No Body Weight Gain at Week 30 and No Documented Symptomatic Hypoglycemia (Plasma Glucose [PG] ≤ 70 mg/dL [3.9 mmol/L]) During 30-Week Treatment Period
Documented symptomatic hypoglycemia was an event during which typical symptoms of hypoglycemia were accompanied by a measured plasma glucose concentration of ≤70 mg/dL (3.9 mmol/L).
Time frame: Baseline up to Week 30
Change in FPG From Baseline to Week 30
Change in FPG was calculated by subtracting baseline value from Week 30 value.
Time frame: Baseline, Week 30
Change in 2-hour PPG From Baseline to Week 30
Change in PPG was calculated by subtracting baseline value from Week 30 value.
Time frame: Baseline, Week 30
Percentage of Participants Reaching HbA1c <7.0% With No Documented Symptomatic Hypoglycemia (PG ≤ 70 mg/dL [3.9 mmol/L]) During 30-Week Treatment Period
Documented symptomatic hypoglycemia was an event during which typical symptoms of hypoglycemia were accompanied by a measured plasma glucose concentration of ≤70 mg/dL (3.9 mmol/L).
Time frame: Baseline up to Week 30
Percentage of Participants Requiring Rescue Therapy During 30-Week Treatment Period
Routine fasting SMPG and central laboratory FPG (and HbA1c after Week 12) values were used to determine the requirement of rescue medication. If fasting SMPG value exceeded the specified limit for 3 consecutive days, the central laboratory FPG (and HbA1c after Week 12) were performed. Threshold values - from Week 8 to Week 12: fasting SMPG/FPG \>240 mg/dL (13.3 mmol/L), and from Week 12 to Week 30: fasting SMPG/FPG \>200 mg/dL (11.1 mmol/L) or HbA1c \>8%.
Time frame: Baseline up to Week 30
Number of Documented Symptomatic Hypoglycemia Events Per Subject-Year
Documented symptomatic hypoglycemia was an event during which typical symptoms of hypoglycemia were accompanied by a measured plasma glucose concentration of ≤70 mg/dL (3.9 mmol/L).
Time frame: First dose of study drug up to 1 day after the last dose administration (median treatment exposure 211 days [FRC], 210 days [Insulin glargine])
Percentage of Participants With Documented Symptomatic Hypoglycemia
Documented symptomatic hypoglycemia was an event during which typical symptoms of hypoglycemia were accompanied by a measured plasma glucose concentration of ≤70 mg/dL (3.9 mmol/L).
Time frame: First dose of study drug up to 1 day after the last dose administration (median treatment exposure 211 days [FRC], 210 days [Insulin glargine])
Percentage of Participants With Severe Symptomatic Hypoglycemia
Severe symptomatic hypoglycemia was an event requiring assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. Plasma glucose measurements might not had been available during such an event, but neurological recovery attributable to the restoration of plasma glucose to normal was considered sufficient evidence that the event had been induced by a low plasma glucose concentration. Severe symptomatic hypoglycemia included all episodes in which neurological impairment was severe enough to prevent self-treatment, and which were thus thought to place participants at risk for injury to themselves or others.
Time frame: First dose of study drug up to 1 day after the last dose administration (median treatment exposure 211 days [FRC], 210 days [Insulin glargine])
The study was conducted at 236 centers in 18 countries. A total of 1930 participants were screened between January 27, 2014 and October 15, 2014. 912 participants were not eligible for run-in-phase mainly due to glycated hemoglobin (HbA1c) value being out of the protocol defined range.
| Milestone | Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) | Insulin Glargine |
|---|---|---|
| Started | 367 | 369 |
| Treated | 365 | 365 |
| Completed | 336 | 355 |
| Not completed | 31 | 14 |
| Withdrew: Randomized but not treated | 2 | 4 |
| Withdrew: Poor compliance to protocol | 4 | 1 |
| Withdrew: Adverse event | 12 | 3 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Other than specified above | 12 | 6 |
Change in HbA1c was calculated by subtracting baseline value from Week 30 value.
| percentage of HbA1c | Insulin Glargine/Lixisenatide Fixed Ratio Combination | Insulin Glargine |
|---|---|---|
| Change in Glycated Hemoglobin (HbA1c) From Baseline to Week 30 | -1.13 ± 0.057 | -0.62 ± 0.055 |
| percentage of participants | Insulin Glargine/Lixisenatide Fixed Ratio Combination | Insulin Glargine |
|---|---|---|
| HbA1c <7.0% | 54.9 | 29.6 |
| HbA1c ≤ 6.5% | 33.9 | 14.2 |
Plasma glucose excursion = 2-hour postprandial glucose (PPG) minus plasma glucose value obtained 30 minutes prior to the start of the meal and before investigational medicinal product (IMP) administration, if IMP was injected before breakfast. Change in plasma glucose excursions was calculated by subtracting baseline value from Week 30 value.
| mmol/L | Insulin Glargine/Lixisenatide Fixed Ratio Combination | Insulin Glargine |
|---|---|---|
| Change in 2-hour Plasma Blood Glucose Excursion From Baseline to Week 30 | -3.9 ± 0.285 | -0.47 ± 0.274 |
Change in body weight was calculated by subtracting baseline value from Week 30 value.
| kg | Insulin Glargine/Lixisenatide Fixed Ratio Combination | Insulin Glargine |
|---|---|---|
| Change in Body Weight From Baseline to Week 30 | -0.67 ± 0.181 | 0.7 ± 0.178 |
Participants recorded a 7-point plasma glucose profile measured before and 2-hours after each meal and at bedtime, two times in a week before baseline, before visit Week 12 and before visit Week 30 and the average value across the profiles performed in the week before a visit for the 7 time points was calculated. Change in average 7 point SMPG was calculated by subtracting baseline value from Week 30 value. The analysis included all scheduled measurements obtained during the study. The missing data was handled by mixed effect model with repeated measures (MMRM) approach.
| mmol/L | Insulin Glargine/Lixisenatide Fixed Ratio Combination | Insulin Glargine |
|---|---|---|
| Mean Change in 7-point Self-monitored Plasma Glucose (SMPG) Profile From Baseline to Week 30 | -1.5 ± 0.137 | -0.6 ± 0.13 |
| percentage of participants | Insulin Glargine/Lixisenatide Fixed Ratio Combination | Insulin Glargine |
|---|---|---|
| Percentage of Participants Reaching HbA1c <7.0% With No Body Weight Gain at Week 30 | 34.2 | 13.4 |
| Units (U) | Insulin Glargine/Lixisenatide Fixed Ratio Combination | Insulin Glargine |
|---|---|---|
| Change in Daily Insulin Glargine Dose From Baseline to Week 30 | 10.64 ± 0.601 | 10.89 ± 0.587 |
Documented symptomatic hypoglycemia was an event during which typical symptoms of hypoglycemia were accompanied by a measured plasma glucose concentration of ≤70 mg/dL (3.9 mmol/L).
| percentage of participants | Insulin Glargine/Lixisenatide Fixed Ratio Combination | Insulin Glargine |
|---|---|---|
| Percentage of Participants Reaching HbA1c <7.0% With No Body Weight Gain at Week 30 and No Documented Symptomatic Hypoglycemia (Plasma Glucose [PG] ≤ 70 mg/dL [3.9 mmol/L]) During 30-Week Treatment Period | 19.9 | 9.0 |
Change in FPG was calculated by subtracting baseline value from Week 30 value.
| mmol/L | Insulin Glargine/Lixisenatide Fixed Ratio Combination | Insulin Glargine |
|---|---|---|
| Change in FPG From Baseline to Week 30 | -0.35 ± 0.142 | -0.46 ± 0.138 |
Change in PPG was calculated by subtracting baseline value from Week 30 value.
| mmol/L | Insulin Glargine/Lixisenatide Fixed Ratio Combination | Insulin Glargine |
|---|---|---|
| Change in 2-hour PPG From Baseline to Week 30 | -4.72 ± 0.322 | -1.39 ± 0.31 |
Documented symptomatic hypoglycemia was an event during which typical symptoms of hypoglycemia were accompanied by a measured plasma glucose concentration of ≤70 mg/dL (3.9 mmol/L).
| percentage of participants | Insulin Glargine/Lixisenatide Fixed Ratio Combination | Insulin Glargine |
|---|---|---|
| Percentage of Participants Reaching HbA1c <7.0% With No Documented Symptomatic Hypoglycemia (PG ≤ 70 mg/dL [3.9 mmol/L]) During 30-Week Treatment Period | 31.7 | 18.6 |
Routine fasting SMPG and central laboratory FPG (and HbA1c after Week 12) values were used to determine the requirement of rescue medication. If fasting SMPG value exceeded the specified limit for 3 consecutive days, the central laboratory FPG (and HbA1c after Week 12) were performed. Threshold values - from Week 8 to Week 12: fasting SMPG/FPG \>240 mg/dL (13.3 mmol/L), and from Week 12 to Week 30: fasting SMPG/FPG \>200 mg/dL (11.1 mmol/L) or HbA1c \>8%.
| percentage of participants | Insulin Glargine/Lixisenatide Fixed Ratio Combination | Insulin Glargine |
|---|---|---|
| Percentage of Participants Requiring Rescue Therapy During 30-Week Treatment Period | 2.7 | 6 |
Documented symptomatic hypoglycemia was an event during which typical symptoms of hypoglycemia were accompanied by a measured plasma glucose concentration of ≤70 mg/dL (3.9 mmol/L).
| events per subject-year | Insulin Glargine/Lixisenatide Fixed Ratio Combination | Insulin Glargine |
|---|---|---|
| Number of Documented Symptomatic Hypoglycemia Events Per Subject-Year | 3.03 | 4.22 |
Documented symptomatic hypoglycemia was an event during which typical symptoms of hypoglycemia were accompanied by a measured plasma glucose concentration of ≤70 mg/dL (3.9 mmol/L).
| percentage of participants | Insulin Glargine/Lixisenatide Fixed Ratio Combination | Insulin Glargine |
|---|---|---|
| Percentage of Participants With Documented Symptomatic Hypoglycemia | 40 | 42.5 |
Severe symptomatic hypoglycemia was an event requiring assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. Plasma glucose measurements might not had been available during such an event, but neurological recovery attributable to the restoration of plasma glucose to normal was considered sufficient evidence that the event had been induced by a low plasma glucose concentration. Severe symptomatic hypoglycemia included all episodes in which neurological impairment was severe enough to prevent self-treatment, and which were thus thought to place participants at risk for injury to themselves or others.
| percentage of participants | Insulin Glargine/Lixisenatide Fixed Ratio Combination | Insulin Glargine |
|---|---|---|
| Percentage of Participants With Severe Symptomatic Hypoglycemia | 1.1 | 0.3 |
Collected over All Adverse Events (AE) were collected from signature of the informed consent form up to the final visit (Week 30) regardless of seriousness or relationship to investigational product.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Insulin Glargine/Lixisenatide Fixed Ratio Combination | — | 20/365 (5.5%) | 81/365 (22.2%) |
| Insulin Glargine | — | 18/365 (4.9%) | 42/365 (11.5%) |
| Event | Insulin Glargine/Lixisenatide Fixed Ratio Combination | Insulin Glargine |
|---|---|---|
| HypoglycaemiaMetabolism and nutrition disorders | 2/365 | 1/365 |
| Hypoglycaemic unconsciousnessNervous system disorders | 2/365 | 0/365 |
| Acute myocardial infarctionCardiac disorders | 2/365 | 0/365 |
| Angina unstableCardiac disorders | 2/365 | 0/365 |
| Non-cardiac chest painGeneral disorders | 0/365 | 2/365 |
| PneumoniaInfections and infestations | 1/365 | 1/365 |
| OsteomyelitisInfections and infestations | 0/365 | 1/365 |
| Wound infectionInfections and infestations | 0/365 | 1/365 |
| Benign breast neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/365 | 0/365 |
| Benign gastric neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/365 | 0/365 |
| Event | Insulin Glargine/Lixisenatide Fixed Ratio Combination | Insulin Glargine |
|---|---|---|
| NauseaGastrointestinal disorders | 38/365 | 2/365 |
| NasopharyngitisInfections and infestations | 32/365 | 32/365 |
| HeadacheNervous system disorders | 21/365 | 10/365 |
| Age, Continuous(years) | Insulin Glargine/Lixisenatide Fixed Ratio Combination | Insulin Glargine | Total |
|---|---|---|---|
| Mean | 59.6 ± 9.4 | 60.3 ± 8.7 | 60.0 ± 9.1 |
| Sex: Female, Male(Participants) | Insulin Glargine/Lixisenatide Fixed Ratio Combination | Insulin Glargine | Total |
|---|---|---|---|
| Female | 202 | 190 | 392 |
| Male | 165 | 179 | 344 |
| Race(Participants) | Insulin Glargine/Lixisenatide Fixed Ratio Combination | Insulin Glargine | Total |
|---|---|---|---|
| Caucasian | 337 | 338 | 675 |
| Black | 17 | 21 | 38 |
| Asian/Oriental | 12 | 8 | 20 |
| Other | 1 | 2 | 3 |
| Ethnicity(Participants) | Insulin Glargine/Lixisenatide Fixed Ratio Combination | Insulin Glargine | Total |
|---|---|---|---|
| Hispanic | 66 | 66 | 132 |
| Not Hispanic | 301 | 303 | 604 |
| OAD Use(Participants) | Insulin Glargine/Lixisenatide Fixed Ratio Combination | Insulin Glargine | Total |
|---|---|---|---|
| Yes | 349 | 350 | 699 |
| No | 18 | 19 | 37 |
| OAD Use at Screening by Class(Participants) | Insulin Glargine/Lixisenatide Fixed Ratio Combination | Insulin Glargine | Total |
|---|---|---|---|
| Metformin | 170 | 190 | 360 |
| Sulfonylurea | 16 | 14 | 30 |
| Sodium glucose co-transporter 2 (SGLT-2) inhibitor | 0 | 1 | 1 |
| Dipeptidyl-peptidase 4 (DPP-4) inhibitor | 2 | 4 | 6 |
| Glinide | 1 | 1 | 2 |
| Metformin + Sulfonylurea | 137 | 118 | 255 |
| Metformin + DPP-4 inhibitor | 20 | 18 | 38 |
| Metfomrin + Glinide | 2 | 3 | 5 |
| Sulfonylurea + DPP-4 inhibitor | 1 | 1 | 2 |
| None | 18 | 19 | 37 |
| Body Mass Index (BMI)(kg/m^2) | Insulin Glargine/Lixisenatide Fixed Ratio Combination | Insulin Glargine | Total |
|---|---|---|---|
| Mean | 31.33 ± 4.25 | 30.96 ± 4.15 | 31.14 ± 4.20 |
| Duration of Diabetes(years) | Insulin Glargine/Lixisenatide Fixed Ratio Combination | Insulin Glargine | Total |
|---|---|---|---|
| Mean | 12.02 ± 6.64 | 12.13 ± 6.85 | 12.08 ± 6.74 |
4 further baseline measures are reported on the registry.
Showing the first 100 of 236 sites across 18 countries. Choose a country and city above to see the rest.
The record gives a start of Jan 2014, a primary completion of Jul 2015 and a completion of Jul 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2017, 1 year 7 months after primary completion. A results delay was requested in Jul 2016.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Insulin Glargine · Lixisenatide